Goat Anti-Human IgG Fc-AF647
Cat. No.:
2048-31
Goat Anti-Human IgG Fc-Alexa Fluor® 647 antibody for use in western blot and for other fluorescent assays.
$116.00
Isotype | Goat IgG |
---|---|
Isotype Control | Goat IgG-AF647 |
Specificity | Reacts with the Fc region of human IgG |
Source | Pooled antisera from goats hyperimmunized with human IgG |
Cross Adsorption | Human IgG Fab, IgM, and IgA; may react with IgG from other species |
Purification Method | Affinity chromatography on human IgG Fc covalently linked to agarose |
Conjugate | AF647 (Alexa Fluor® 647) |
Buffer Formulation | Phosphate buffered saline containing < 0.1% sodium azide |
Clonality | Polyclonal |
Concentration | 0.5 mg/mL |
Volume | 1.0 mL |
Recommended Storage | 2-8°C; Avoid exposure to light |
Trademark Information | Alexa Fluor® is a registered trademark of Thermo Fisher Scientific, Inc. or its subsidiaries |
Applications | Quality tested applications for relevant formats include - ELISA 1 FLISA Other referenced applications for relevant formats include - Western Blot 2,3 Surface Plasmon Resonance 4 |
RRID Number | AB_2795692 |
Documentation
Certificate of Analysis Lookup
Enter the Catalog Number and Lot Number for the Certificate of Analysis you wish to view
- 1. Wang Q, Chen K, Liu F, Zhao F, Gupta S, Zhang N, et al. Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist. PLoS One. 2010;5(9):e12734. (ELISA)
- 2. Shen X, Hu G, Jiang S, He F, Xing W, Li L, et al. Engineering and characterization of a baculovirus-expressed mouse/human chimeric antibody against transferrin receptor. Protein Eng Des Sel. 2009;22:723-31. (WB)
- 3. Djoumerska-Alexieva IK, Dimitrov JD, Voynova EN, Lacroix-Desmazes S, Kaveri SV, Vassilev TL. Exposure of IgG to an acidic environment results in molecular modifications and in enhanced protective activity in sepsis. FEBS J. 2010;277:3039-50. (WB)
- 4. Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol. 2009;131:308-16. (Surface Plasmon Resonance)
See All References